留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

重要提示

《药学实践与服务》杂志不接收生物战剂、毒剂相关内容的稿件。对于涉军信息类论文如需投稿,请务必投稿前电话或邮箱咨询。联系电话:021-81871323,邮箱:yxsjzzs@163.com。敬请谅解,谢谢配合!

《药学实践与服务》编辑部

免责声明

《药学实践与服务》杂志目前不收取审稿费、版面费、加急费等费用,如收到邮件声称是编辑部X编辑,要求加作者微信的,请谨防财产损失!编辑部用于作者校稿时微信绑定的邮件是通过yxsjzzs@163.com发送的,标题是《药学实践与服务》XML数字出版服务微信绑定,请区分开!

P53-MDM2界面的肽类及拟肽类抑制剂的研究进展

李翔 邹燕 吴茂诚 黄婷 胡宏岗 吴秋业

李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业. P53-MDM2界面的肽类及拟肽类抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
引用本文: 李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业. P53-MDM2界面的肽类及拟肽类抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
LI Xiang, ZOU Yan, WU Maocheng, HUANG Ting, HU Honggang, WU Qiuye. Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
Citation: LI Xiang, ZOU Yan, WU Maocheng, HUANG Ting, HU Honggang, WU Qiuye. Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004

P53-MDM2界面的肽类及拟肽类抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.004

Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface

  • 摘要: 当前,肿瘤疾病以日益增高的发病率越来越受到人们的重视。抑制P53-MDM2的相互作用已经成为治疗癌症药物设计的重要靶标,通过各种药物筛选手段,研究人员发现了许多肽类及小分子抑制剂。综述近年来国内外关于肽类及拟肽类的P53-MDM2抑制剂的研究进展。
  • [1] Oliner JD, Kinzler KW, Meltzer PS, et al. Amplication of a gene encoding a p53-associated protein in human sarcomas[J]. Nature, 1992, 358: 80-83.
    [2] Levine AJ. P53, the cellular gate keeper for growth and division[J]. Cell, 1997, 88(3): 323-331.
    [3] Bert V, David L, Arnold JL. Surfing the p53 network[J]. Nature, 408: 307-310.
    [4] Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53[J]. Nature, 1993, 362: 857-860.
    [5] Pickskey SM, Lane DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53[J]. BioEssays, 1993, 15: 689-690.
    [6] Raymond EM, Melanie C, Tina ND, et al. Direct inhibition of the NOTCH transcription factor complex[J]. Nature, 2009, 462(7270): 182-188.
    [7] Wu X, Bayle JH, Olson D, et al. The P53-mdm-2 autoregulatory feedback loop[J]. Genes Devel, 1993, 7(7a): 1126-1132.
    [8] Almerico AM, Tutone M, Pantano L, et al. Molecular dynamics studies on Mdm2 complexes: an analysis of the inhibitor influence[J]. Biochem Biophys Res Commun, 2012, 424(2): 341-347.
    [9] Meng W, Brigance RP, Chao HJ,et al. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxa mides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors[J]. J Med Chem, 2010, 53(15): 5620-5628.
    [10] Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the P53 pathway by small-molecule antagonists of MDM2[J]. Science, 2004, 303(5659): 844-848.
    [11] Wang B, Fang L, Zhao H, et al. MDM2 inhibitor nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells[J]. Acta Biochim Biophys Sin (Shanghai), 2012, 44(8): 685-691.
    [12] Warner WA, Sanchez R, Dawoodian A, et al. Identification of FDA-approved drugs that computationally bind to MDM2[J]. Chem Biol Drug Des, 2012, 80(4): 631-637.
    [13] Zhuang C, Miao Z, Zhu L, et al. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the P53-MDM2 protein-protein interaction[J]. Eur J Med Chem, 2011, 46(11): 5654-5661.
    [14] Grasberger BL, Lu T, Schubert C, et al. Discovery and cocrystalstructure of benzodiazepinedione MDM2 antagonists that activate P53 in cells. J Med Chem, 2005, 48(4): 909-912.
    [15] Mohammad RM, Wu J, Azmi AS, et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals[J]. Mol Cancer, 2009, 8: 115.
    [16] Andrea GC. Protein-protein interfaces: mimics and inhibitors[J]. Curr Opin Chem Biol, 2001, 5:654-659.
    [17] Arkin MR and Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream[J]. Nat Rev Drug Discov, 2004, 3(4): 301-317.
    [18] Pazgier M, Liu M, Zou G, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX[J]. Proc Natl Acad Sci(USA), 2009, 106(12): 4665-4670.
    [19] Chang YS, Graves B, Guerlavais V, et al. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy[J]. Proc Natl Acad Sci USA, 2013, 110(36): E3445-E3454.
    [20] Li C, Pazgier M, Liu M, et al. Apamin as a template for structure-based rational design of potent peptide activators of p53[J]. Angew Chem Int Ed Engl, 2009, 48(46): 8712-8715.
    [21] Li C, Zhan C, Zhao L, et al. Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction[J]. Bioorg Med Chem, 2013, 21(14): 4045-4050.
    [22] Hu Y, Li X, Sebti SM, et al. Design and synthesis of peptides: a new class of peptide mimics[J]. Bioorg Med Chem Lett, 2011, 21(5): 1469-1471.
    [23] Noguchi T, Oishi S, Honda K, et al. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors[J]. Bioorg Med Chem Lett, 2013, 23(13): 3802-3805.
    [24] Duncan SJ, Gruschow S, Williams DH, et al. Isolation and structure elucidation of chlorofusin, a novel P53-MDM2 antagonist from a Fusarium sp[J]. J Am Chem Soc, 2001, 123: 554-560.
    [25] Lee SY and Boger DL. Synthesis of the chlorofusin cyclic peptide[J]. Tetrahedron, 2009, 65(16): 3281-3284.
    [26] Sakurai K and Kahne D. Design and synthesis of functionalized trisaccharides as P53-peptide mimics[J]. Tetrahedron Lett, 2010, 51(29): 3724-3727.
    [27] Phan J, Li Z, Kasprzak A, et al. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX[J]. J Biol Chem, 2010, 285(3): 2174-2183.
    [28] Liu M, Pazgier M, Li C, et al. A left-handed solution to peptide inhibition of the P53-MDM2 interaction[J]. Angew Chem Int Ed Engl, 2010, 49(21): 3649-3652.
    [29] Li C, Pazgier M, Li J, et al. Limitations of peptide retro-inverso isomerization in molecular mimicry[J]. J Biol Chem, 2010, 285(25): 19572-19581.
    [30] Harker EA and Schepartz A. Cell-permeable beta-peptide inhibitors of p53/hDM2 complexation[J]. Chembiochem, 2009, 10(6): 990-993.
    [31] Hintersteiner M, Kimmerlin T, Garavel G, et al. A highly potent and cellularly active beta-peptidic inhibitor of the p53/hDM2 interaction[J]. Chembiochem, 2009, 10(6): 994-998.
    [32] Yamada S, Kanno H and Kawahara N. Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53[J]. J Neurooncol, 2012, 109(1): 7-14.
    [33] Li C, Shen J, Wei X, et al. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy[J]. J Drug Target, 2012, 20(3): 264-271.
    [34] Jeong WJ, Lee MS and Lim YB. Helix stabilized, thermostable, and protease-resistant self-assembled peptide nanostructures as potential inhibitors of protein-protein interactions[J]. Biomacromolecules, 2013, 14(8): 2684-2689.
    [35] Muppidi A, Wang Z, Li X, et al. Achieving cell penetration with distance-matching cysteine cross-linkers: a facile route to cell-permeable peptide dual inhibitors of Mdm2/Mdmx[J]. Chem Commun (Camb), 2011, 47(33): 9396-9398.
    [36] Muppidi A, Li X, Chen J, et al. Conjugation of spermine enhances cellular uptake of the stapled peptide-based inhibitors of p53-Mdm2 interaction[J]. Bioorg Med Chem Lett, 2011, 21(24): 7412-7415.
    [37] Madden MM, Muppidi A, Li Z, et al. Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition[J]. Bioorg Med Chem Lett, 2011, 21(5): 1472-1476.
  • [1] 孙波, 吕宗强, 罗宁, 李荣, 王洪祥, 陈菊祥.  Angiopep-2修饰的细菌外囊泡载药系统治疗胶质母细胞瘤效果研究 . 药学实践与服务, 2025, 43(10): 481-490. doi: 10.12206/j.issn.2097-2024.202506017
    [2] 于翔, 贾培培, 李欣颖, 杨君君, 郭高峰, 陆连芳.  M2型巨噬细胞外泌体喷剂对压力性损伤的疗效及作用机制 . 药学实践与服务, 2025, 43(9): 436-442. doi: 10.12206/j.issn.2097-2024.202503066
    [3] 王兰英, 陆高峰, 袁梅娟, 李卫玲, 罗盈怡, 徐峰.  社区药学门诊服务对2型糖尿病患者的管理效果分析 . 药学实践与服务, 2025, 43(7): 357-361. doi: 10.12206/j.issn.2097-2024.202407002
    [4] 魏莱, 董国强, 盛春泉.  靶向SARS-CoV-2主蛋白酶的PROTAC设计、合成与蛋白降解活性研究 . 药学实践与服务, 2025, 43(5): 235-241, 258. doi: 10.12206/j.issn.2097-2024.202503063
    [5] 徐尧, 马春辉, 李志勇.  高血压对大鼠心血管纤维化及sFRP2表达的影响 . 药学实践与服务, 2025, 43(4): 180-184. doi: 10.12206/j.issn.2097-2024.202409055
    [6] 赵凤平, 于镇铭, 陈熹, 姜棋文, 郑灿辉, 陈新.  醛脱氢酶2改善铁死亡相关疾病预后的研究进展 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202411043
    [7] 郭静, 康金龙, 李强, 赵琳, 刘骥, 徐学武.  利多卡因不同给药途径对麻醉诱导气管插管心血管应激反应的抑制作用 . 药学实践与服务, 2025, 43(6): 303-306. doi: 10.12206/j.issn.2097-2024.202502009
    [8] 江冼芮, 段雅倩, 刘畅, 张成中.  淫羊藿中黄酮苷类化合物的群体感应抑制作用研究 . 药学实践与服务, 2025, 43(4): 169-173. doi: 10.12206/j.issn.2097-2024.202409060
    [9] 崔潆心, 魏京京, 叶晓霞, 乐健.  拉曼光谱在皮肤外用制剂质量与体外透皮研究中的应用 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202409017
    [10] 王建平, 杨志晖, 戴博, 宋青.  军队医院制剂室历史回顾及发展展望 . 药学实践与服务, 2025, 43(12): 1-6. doi: 10.12206/j.issn.2097-2024.202504050
    [11] 高洁, 林心兰, 王兆骞, 张青亭, 李静静, 张凤.  生物制剂治疗强直性脊柱炎的研究进展 . 药学实践与服务, 2025, 43(7): 320-324. doi: 10.12206/j.issn.2097-2024.202502005
    [12] 赵全公, 王国坤, 徐志云.  虾青素通过激活Nrf2/HO-1通路抑制瓣膜间质细胞钙化 . 药学实践与服务, 2025, 43(6): 283-287. doi: 10.12206/j.issn.2097-2024.202412057
    [13] 施乔, 韩贵焱, 张俊腾, 刘娜.  新型Hsp90抑制剂的设计合成及其抗真菌和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(3): 124-135. doi: 10.12206/j.issn.2097-2024.202501019
    [14] 周文艳, 胡珊珊, 张万年, 庄春林.  Keap1-Nrf2通路在炎症疾病中的研究进展 . 药学实践与服务, 2025, 43(3): 97-108, 116. doi: 10.12206/j.issn.2097-2024.202405013
    [15] 魏莱, 董国强.  SARS-CoV-2主蛋白酶抑制剂和降解剂研究进展 . 药学实践与服务, 2025, 43(6): 259-269, 297. doi: 10.12206/j.issn.2097-2024.202503064
    [16] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [17] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [18] 张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳.  基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
    [19] 白学鑫, 陈玉平, 盛春泉, 武善超.  具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 503-507. doi: 10.12206/j.issn.2097-2024.202405009
    [20] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
  • 加载中
计量
  • 文章访问数:  4837
  • HTML全文浏览量:  448
  • PDF下载量:  353
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-11-25
  • 修回日期:  2014-03-31

P53-MDM2界面的肽类及拟肽类抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.004

摘要: 当前,肿瘤疾病以日益增高的发病率越来越受到人们的重视。抑制P53-MDM2的相互作用已经成为治疗癌症药物设计的重要靶标,通过各种药物筛选手段,研究人员发现了许多肽类及小分子抑制剂。综述近年来国内外关于肽类及拟肽类的P53-MDM2抑制剂的研究进展。

English Abstract

李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业. P53-MDM2界面的肽类及拟肽类抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
引用本文: 李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业. P53-MDM2界面的肽类及拟肽类抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
LI Xiang, ZOU Yan, WU Maocheng, HUANG Ting, HU Honggang, WU Qiuye. Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
Citation: LI Xiang, ZOU Yan, WU Maocheng, HUANG Ting, HU Honggang, WU Qiuye. Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
参考文献 (37)

目录

    /

    返回文章
    返回